ArticleFrontiers in pharmacology2021
Berberine and Its Main Metabolite Berberrubine Inhibit Platelet Activation Through Suppressing the Class I PI3Kβ/Rasa3/Rap1 Pathway.
Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 29 citations in OpenAlex.
- Article
- Protopanaxatriol ameliorates diabetic retinopathy by regulating mTOR/G6PD mediated pentose phosphate pathway.Journal of natural medicines · 2026Article
- Small RNA sequencing identifies tsRNA-05020 as a potential regulator of cervical cancer progression.Turkish journal of biology = Turk biyoloji dergisi · 2026Article
- Navigating the Effects of Anti-Atherosclerotic Supplements and Acknowledging Associated Bleeding Risks.International journal of molecular sciences · 2025Review
- Antithrombotic Effect ofInternational journal of molecular sciences · 2025Article
- [Berberine ameliorates coronary artery endothelial cell injury in Kawasaki disease through complement and coagulation cascades].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2025Article
- Understanding the Relationship Between Cerebrovascular Disease and the Gut Microbiome.Stroke (Hoboken, N.J.) · 2025Review
- Exploration of Phytochemicals as Anti-biofilm Agents against Pathogenic Bacteria: Their Potential and Challenges.Infectious disorders drug targets · 2025Review
- Berberine and its derivatives: mechanisms of action in myocardial vascular endothelial injury - a review.Frontiers in pharmacology · 2025Review
- A review of natural compounds to regulate platelet aggregation: molecular mechanism and research advance.Frontiers in pharmacology · 2025Review
- Natural active herbal monomers for the treatment of thromboembolic diseases: a review.Frontiers in pharmacology · 2025Review
- A Descriptive Review of the Antioxidant Effects and Mechanisms of Action of Berberine and Silymarin.Molecules (Basel, Switzerland) · 2024Review
- Berberine Targets PKM2 to Activate the t-PA-Induced Fibrinolytic System and Improves Thrombosis.Pharmaceuticals (Basel, Switzerland) · 2024Article
- An early warning indicator of mortality risk in patients with COVID-19: the neutrophil extracellular traps/neutrophilic segmented granulocyte ratio.Frontiers in immunology · 2024Article
- Exosomes-transferred LINC00668 Contributes to Thrombosis by Promoting NETs Formation in Inflammatory Bowel Disease.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Autophagic degradation of LOX-1 is involved in the maintenance of vascular integrity injured by oxLDL and protected by Berberine.International journal of biological sciences · 2023Article
- Novel strategies in antithrombotic therapy: targeting thrombosis while preserving hemostasis.Frontiers in cardiovascular medicine · 2023Review
- Berberine in Sepsis: Effects, Mechanisms, and Therapeutic Strategies.Journal of immunology research · 2023Review
- Berberine Overcomes Gemcitabine-Associated Chemoresistance through Regulation of Rap1/PI3K-Akt Signaling in Pancreatic Ductal Adenocarcinoma.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Berberrubine, a Main Metabolite of Berberine, Alleviates Non-Alcoholic Fatty Liver DiseaseFrontiers in pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.